Drug Profile
SWT 06101
Alternative Names: SWT-06101Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator SWITCH Biotech (CEASED)
- Developer SWITCH Biotech
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibromyalgia
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Fibromyalgia in USA (Topical)